News Takeda Pharmaceutical Company Limited

Equities

4502

JP3463000004

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-06-06 am EDT			5-day change	1st Jan Change
4,203 ^JPY	-0.28%		+2.61%	+3.68%

06:00am	Torrent Pharma Signs Deal with Japan's Takeda to Market Acid-Related Disorders Drug in India	MT
Jun. 04	Transcript : Takeda Pharmaceutical Company Limited - Special Call

Summary

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Torrent Pharma Signs Deal with Japan's Takeda to Market Acid-Related Disorders Drug in India	12:00am	MT
Takeda Pharmaceutical - Notice Concerning Withdrawal of Shelf Registration Statement and Filing of New Shelf Registration Statement in Japan	Jun. 04	AQ
Transcript : Takeda Pharmaceutical Company Limited - Special Call	Jun. 03
Takeda Pharmaceutical, Pfizer Say Phase 3 Trial Assessing Blood Cancer Combination Therapy Met Co-Primary Endpoints	Jun. 03	MT
Takeda Says Narcolepsy Drug Meets Main, Secondary Goals in Trial	Jun. 03	MT
Takeda’s TAK-861 Phase 2b Late-Breaking Data Presentations at SLEEP 2024 Demonstrate Clinically Meaningful Impact of Oral Orexin Agonist in Narcolepsy Type 1 Compared to Placebo	Jun. 03	BU
GSK blood cancer drug nearly halves risk of death in late-stage trial	Jun. 02	RE
Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma	Jun. 01	CI
Takeda Pharmaceutical Says Recombinant ADAMTS13 Gets Approval Recommendation From European Medicines Agency's CHPM	May. 31	MT
Takeda Gets CHMP Approval for Recombinant ADAMTS13	May. 31	DJ
Takeda Receives Positive CHMP Opinion for Recombinant ADAMTS13 (rADAMTS13) in Congenital Thrombotic Thrombocytopenic Purpura (cTTP)	May. 31	BU
Takeda Receives Positive CHMP Opinion for Recombinant ADAMTS13 in Congenital Thrombotic Thrombocytopenic Purpura	May. 31	CI
BHP pursuit of Anglo American highlights corporate-led UK M&A upswing	May. 30	RE
Takeda Pharmaceutical : Other items which are provided electronically	May. 29	PU
TAKEDA PHARMACEUTICAL : Form 6-K	May. 21	PU
Takeda Canada Completes LOI Stage for Post-Transplant Cytomegalovirus Treatment	May. 16	MT
Takeda Canada Inc. concludes Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) for LIVTENCITY® (maribavir) for the treatment of adults with a post-transplant cytomegalovirus (CMV) infection	May. 16	AQ
Takeda Pharmaceutical's Dengue Vaccine Granted WHO Prequalification	May. 15	MT
FDA extends review of Ascendis Pharma's hormone disorder therapy	May. 14	RE
Scilex Holding Says Federal Court Approved Settlement With Takeda Pharmaceutical in Gloperba Patent Dispute	May. 14	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Takeda Pharmaceutical Company Limited

Equities

4502

JP3463000004

Summary

Filters